Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Information source: University of Pittsburgh
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Enterobacteriaceae Infections
Phase: N/A
Status: Active, not recruiting
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s):
Brian Potoski, Pharm D, Principal Investigator, Affiliation: UPMC
Summary
This research will be conducted to determine whether risk factors exist for
piperacillin/tazobactam resistance in ESBL organisms.
Clinical Details
Official title: Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms
Study design: Time Perspective: Retrospective
Primary outcome: This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.
Detailed description:
This is chart review at UPMC. NO human subject interaction will occur.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical information is collected by chart review of "case" and "control" patients.
- A "case A" patient is defined as follows: One or more clinical cultures are positive
for an ESBL producing bacteria and the organism is piperacillin/tazobactam resistant.
- A "case B" patient is defined as follows: One or more clinical cultures are positive
for an ESBL producing bacteria and the organism is piperacillin/tazobactam
susceptible.
- Additionally, 1 control patient in the hospital at the same time as the case patients
will be randomly selected for each case and are not in either case group.
Exclusion Criteria:
- Patients < 18 years of age
Locations and Contacts
UPMC, Pittsburgh, Pennsylvania 15213, United States
Additional Information
Starting date: November 2007
Last updated: August 15, 2012
|
